GRAIL Inc. Ordinary Shares GRAL 深 沪
等待开盘 09-26 09:30:00 美东时间
47.96
+1.380
+2.96%
华盛通- 最 高47.96
- 今 开45.07
- 成交量 62.83万股
- 最 低 43.82
- 昨 收 46.58
- 总市值 17.29亿
- 52周最高 63.99
- 市盈率 静 --
- 换手率 1.74%
- 52周最低 12.33
- 委 比 -7.07%
- 总股本 3604.78万
- 历史最高 63.99
- 量 比 0.66
- 振 幅 8.89%
- 历史最低 12.33
- 每 手 1
- 风险率 10.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GRAIL To Present New Data Highlighting Galleri MCED Test Performance And Safety From Registrational PATHFINDER 2 Study At ESMO Congress 2025
First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket Approval Application
09-23 21:04
GRAIL shares are trading higher after the company reported better-than-expected Q2 EPS results.
GRAIL shares are trading higher after the company reported better-than-expected...
09-11 23:28
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif., Aug. 29, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has g...
08-30 04:01
GRAIL Q2 EPS $(3.18) Beats $(3.90) Estimate, Sales $35.533M Miss $37.667M Estimate
GRAIL (NASDAQ:GRAL) reported quarterly losses of $(3.18) per share which beat the analyst consensus estimate of $(3.90) by 18.36 percent. This is a 40 percent increase over losses of $(5.30) per share from the same
08-13 04:02
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Wall Street Rises Ahead Of Fed, Payment Stocks Fall On Stablecoin Bill: What's Driving Markets Wednesday?
U.S. stocks inched higher by midday Wednesday, as traders weighed geopolitical uncertainty and awaited the Federal Reserve's June policy decision.
06-19 00:31
Grail posts latest trial data for Galleri cancer detection test
Grail (NASDAQ:GRAL) announced Wednesday that its Galleri test led to improved cancer detection when added to standard-of-care cancer screening in its PATHFINDER 2 registrational trial. Citing topline ...
06-18 22:14
GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study
Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study MENLO PARK, Calif., June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL...
06-18 21:01
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif., May 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has gr...
05-31 04:05
GRAIL to Present at Jefferies Global Healthcare Conference 2025
MENLO PARK, Calif., May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company m...
05-22 04:05
